Most chapters recommend starting low and going slow on dosages, being alert to potential risk factors, handling emerging problems promptly, ensuring compliance by educating patients, and avoiding polypharmacy as much as possible. Monotherapy goes counter to the current practice of combining two or more drugs of the same or differing classes in order to achieve a full response, such as using several antidepressants, with or without other augmenters, for treatment-resistant depression (1). Discussing the effects of selective serotonin reuptake inhibitors (SSRIs) on sexual functioning, the authors suggest switching to another antidepressant known to cause fewer sexual side effects or using specific antidotes, but they do not consider adding another antidepressant, such as mirtazapine, nefazodone, or bupropion, to the SSRI to minimize sexual side effects. When it comes to the management of addictive behaviors or bipolar disorder, the authors appropriately recommend polypharmacy. Management of the side effects of beta blockers, sedative-hypnotics, and cognitive enhancers is discussed in a separate chapter.